Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
Go back to Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema| Merck & Co. (NYSE: MRK) | Delayed: 148.78 +0.80 (0.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $147.98 | 52 Week High | $65.46 | |||
| Open | $148.06 | 52 Week Low | $47.97 | |||
| Day High | $149.98 | P/E | 101.21 | |||
| Day Low | $147.48 | EPS | $1.47 | |||
| Volume | 8,290,254 | |||||
